Hesperidin+ By Biotex Life Solutions: A Comprehensive Narrative Product Review of Antioxidant, Anti-Inflammatory, Antiviral, and Anticancer Evidence

Abstract

Background: Oxidative stress and chronic low-grade inflammation are reciprocally reinforcing, with reactive oxygen species as the shared upstream trigger underlying cardio metabolic, viral and neoplastic disease. Multi-ingredient nutraceuticals engaging both axes through distinct but convergent phytochemistry offer a mechanistically plausible strategy.

Aim. This narrative product review evaluates per-ingredient evidence for each of the six actives in Hesperidin+, a polyphenol-rich multi-ingredient nutraceutical developed by Biotex Life Solutions: hesperidin (500 mg), Bambusa arundinacea crystals/tabasheer (200 mg), rutin (100 mg), Citrus limon fruit extract (50 mg), Rubia cordifolia root extract (50 mg), and Punica granatum fruit extract (50 mg).

Methodology. PubMed/PMC, ScienceDirect, MDPI, Frontiers, Crossref and the Jenni library were searched for English-language peer-reviewed studies between January 2016 and July 2026. Priority was assigned to RCTs, meta-analyses, mechanistic studies and high-quality systematic reviews.

Key findings. A 2026 meta-analysis of 10 RCTs (n = 532) showed hesperidin supplementation significantly reduced CRP/hs-CRP (SMD −0.43; 95% CI −0.71 to −0.15; P = 0.002) and TNF-α (SMD −0.51; 95% CI −0.95 to −0.07; P = 0.02), with IL-6 reaching statistical significance in adults with diagnosed disease (SMD −0.38; 95% CI −0.72 to −0.04; P = 0.03). Eriomin® (70% eriocitrin, 5% hesperidin, 4% naringin) at 200 mg/day over 12 weeks reduced hyperglycaemia by 6% and increased GLP-1 by 22% in a prediabetes RCT with concurrent microbiota rebalancing. Molecular-docking and enzyme-inhibition data indicate hesperidin and hesperetin interact with multiple SARS-CoV-2 entry-associated targets, with hesperidin's Mpro IC₅₀ reported at 51.5 µM and 5.5 mM in biochemical assays. Pomegranate peel extract inhibits SARS-CoV-2 spike binding to the human ACE2 receptor in vitro. Anticancer activity is documented across multiple cell-line models through NF-κB suppression, caspase activation and cell-cycle arrest.

Conclusion. Hesperidin+ presents a coherent multi-target mechanistic rationale centred on Nrf2/ARE and NF-κB pathways. Per-ingredient human evidence supports antioxidant and anti-inflammatory claims; antiviral and anticancer signals are predominantly preclinical. A formulation-level pharmacokinetic and efficacy study is required before clinical claims can be made for the finished product.